Stockhouse.com: Taking it to the street
Latest Broadcasts
T.FR
Natural Resources
V.AIX
Natural Resources.
OMCY
Internet/Technology
V.KTN
Natural Resources, Metals and Mining
T.ND
Natural Resources
V.GRI
Natural Resources
An excellent place to start your search for new investments!
add to favorites print

CV Therapeutics looks to be on a good trajectory.

CV Therapeutics (NASDAQ: CVTX, Stock Forum) probably deserves yet another look from biotech investors. Its last quarter was better than expected, and the company looks like it is on a very good trajectory.

In the first quarter, CVTX managed to do a better job with expenses than it recently has and sales of its core product, chronic angina drug Ranexa, jumped.

In light of this, the stock may be too low. It trades at $8.70, well below its 52-week high of $13.74.

For Q1, CVXT reported a net loss of $31.9 million. In the same period a year ago, the firm had a net loss of $34.1 million. Revenue went to $22.8 million from just over $15 million last year.

CV also disclosed what most investors view as very good news. The company said that that TPG-Axon Capital agreed to pay CV Therapeutics up to $185 million in exchange for rights to 50% of the royalty on North American sales of the Lexiscan (TM) (regadenoson) injection. Is the firm giving up too much of its future sales? It is too early to tell.

At 5x sales, the shares look attractive.

ABOUT THE AUTHOR
From the news desk of 24/7 Wall St.

This report was prepared by 24/7 Wall St., LLC exclusively for Stockhouse. 

 
print
 
Stockhouse Conflict and Disclosure Policy:

Stockgroup Media Inc., owners and operators of Stockhouse.com, has established the following rules to ensure that there is no appearance of impropriety on the part of any Stockhouse Editorial writers ("Writers"). The content of Stockhouse Editorial articles (the "Articles") are the opinion of the Writer and any reliance on the content of these articles is at your sole risk. Our Writers are not registered investment advisors. You should not make any kind of investment decision in relation to Articles or stocks discussed in them without obtaining advice from a registered investment advisor.

Facts relied upon by our Writers are generally provided by the subject companies or gathered by our Writers from other public and/or private sources. These facts may be in error and if so, the opinions of our Writers may be materially different.

Writers may own, buy, or sell shares in public companies mentioned in their Articles, but in the Article they must prominently state their ownership position. Thus, a conflict may exist. Writers are not permitted to write Articles that attempt to benefit persons connected to the Writer, such as family or friends, except where disclosure is made in the same way as if the Writer him/herself owns stock.

Writers cannot solicit, accept, or agree to receive anything of value given or paid with the intent of influencing their Articles.

Stockhouse notifies each Writer about these rules, and we rely on the integrity of our Writers to ensure that our rules are followed.

 
 
 
 
 
Today's Feature  
 
Alix Resources Corp
Large Property Inventory Allows for Year Round Exploration & Increased Opportunity for Significant Discoveries Alix Resources has a portfolio of properties located in Alaska, Nunavut Territory, Arizona and Canada. Much of the Company’s current focus is on its coal properties in Saskatchewan and Manitoba. Property Profiles Coal: Saskatchewan The coal dispositions sit between the Wapawekka Lake and the Adamas discovery...